

ASX Announcement

23 April 2026

Cogstate Limited
ABN 80 090 975 723

Level 32
367 Collins Street
Melbourne, Vic, 3000
Australia

P +61 3 9664 1300
F +61 3 9664 1301
W cogstate.com

Appointment of Non-Executive Director

Cogstate Ltd (ASX:CGS), a global leader in clinical trial endpoint data quality and digital cognitive assessments, today announces the appointment of Mr. Darryl Inns as a Non-Executive Director, effective 01 May 2026.

Mr. Inns is an experienced former ASX-listed company Chief Financial Officer with more than 30 years' experience in finance, accounting and executive leadership, including over 20 years as CFO of ASX200 companies. He has held senior roles at Uniti Group Limited (ASX: UWL), Vocus Limited (ASX: VOC), iSelect Limited (ASX: ISU) and M2 Group Limited (formerly ASX: MTU), where he played a key role in driving growth, executing complex M&A, and leading capital management programs and capital raisings.

Commenting on the appointment, Cogstate Chair, Martyn Myer AO, said, "Cogstate has entered the next phase in its development, characterised by a more mature operational and financial profile and an expanding global footprint. Darryl's deep financial acumen, public markets experience and track record in capital management will be invaluable as we continue to execute our strategy and focus on sustainable long-term value creation for shareholders. His appointment also forms an important part of our ongoing Board renewal program and ensures we maintain a balanced mix of skills aligned to Cogstate's future needs."

Mr. Inns replaces Mr. Richard van den Broek, who stepped down from the Board in May 2025 as part of the Company's planned Board succession and renewal program. His appointment brings to the Cogstate Board a depth of financial, capital markets and investor relations expertise, adding further depth and strength to the Board.

Mr. Inns has extensive experience in governance, risk and compliance, including reporting to and engaging with Audit & Risk Committees. He is a Fellow of CPA Australia, and a Graduate of the Australian Institute of Company Directors.

Mr. Inns will join Cogstate's Audit, Risk & Compliance Committee, replacing Mr. Richard Mohs who will step down from this committee. Mr. Inns will also join the Nomination Committee.

Cogstate has implemented several Board Committee changes to further enhance independence and governance. From 01 January 2026, Mr. Martyn Myer has stepped down from both the Audit, Risk & Compliance Committee (Chaired by Ms. Ingrid Player) and the Remuneration Committee (Chaired by Ms. Kim Wenn).

This announcement was authorised for release by the Board of Cogstate Ltd. For further information contact: investor@cogstate.com

About Cogstate

Cogstate Ltd (ASX: CGS) is a global Central Nervous System (CNS) endpoint innovations company that partners with drug developers to power complex neuroscience studies. Cogstate uniquely specializes in the science and service of CNS measurement to ensure clinical trial endpoint data is as accurate as it is actionable. Our applied technology solutions include fit-for-purpose data quality programs, advanced analytics, and digital cognitive testing to identify clear signals for confident decision-making. Building upon 25 years of customized collaborations, Cogstate is accelerating the next generation of CNS therapies. In the Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and scientifically validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform patients and save physician time. For more information, please visit www.cogstate.com.

For personal use only